Abstract To analyze the effect of the multimodal analgesia by ropivacaine-parecoxib sodium for postoperative analgesia of women with tubal infertility after hysteroscopy. Methods: 112 patients with tubal infertility who underwent laparoscopic surgery were selected and divided into observation group (56 cases) and control group (56 cases) according to random number table method from January 2018 to January 2019. The women in both groups were injected 0.5% ropivacaine 10ml around each laparoscopic incision. The women in the observation group were given intravenous injection parecoxib sodium 40mg, and the women in the control group were given the same volume of 0.9% sodium chloride. Visual analogue scale (VAS) was used to evaluate the degree of pain of women in both groups at 1, 4, 12, 24 and 48 hours after operation. The restlessness score and Ramsay sedation score at 5 minutes and immediately after extubation, the dosage of remifentanil during operation, and the pressing times of patient-controlled intravenous analgesia (PCA) pump after operation, and the incidence of adverse reactions of women were compared between the two groups. Results: VAS scores at different time points after extubation of women in the observation group were significant lower than those of women in the control group. The scores of restlessness immediately and 5min after extubation of women in the observation group (1.38±0.71 points and 0.74±0.48 points) were significant lower than those (1.94±0.77 points and 1.43±0.45 points) of women in the control group. The scores of Ramsay sedation immediately and 5 min after extubation of women in the observation group (1.86±0.55 points and 2.65±0.72 points) were significant higher than those (1.55±0.58 points and 2.14±0.64 points) of women in the control group. The pressing times of PCA pump after operation of women in the observation group (2.75±1.48 times) was significant lower than that (5.39±1.58 times) of women in the control group (all P<0.05). There were no significant differences in the dosage of remifentanil and the total incidence (14.3% vs. 21.4%) of postoperative adverse reactions, such as nausea and vomiting, respiratory depression, incision edema, and infection of women between the two groups (P>0.05). Conclusion: Ropivacaine combined with parecoxib sodium multimodal analgesia can effectively reduce the pain state of patients after uterine and abdominal surgery, and can reduce the occurrence of postoperative adverse reaction, which is worthy of clinical popularization and application.
|
|
|
|
|